Peripheral accumulation of newly produced T and B lymphocytes in natalizumab-treated multiple sclerosis patients by C.ZANOTTI et al.
ava i l ab l e a t www.sc i enced i r ec t . com
C l i n i ca l Immuno logy
www.e l sev i e r . com/ l o ca t e / y c l im
Clinical Immunology (2012) 145, 19–26Peripheral accumulation of newly produced T and B
lymphocytes in natalizumab-treated multiple
sclerosis patients
Cinzia Zanotti a, Marco Chiarini a, Federico Serana a, Alessandra Sottini a,
Emirena Garrafa a, Fabio Torri b, Luigi Caimi a, Sarah Rasia c,
Ruggero Capra c, Luisa Imberti a,⁎a Biotechnology Laboratory, Diagnostics Department, Spedali Civili di Brescia, P.le Spedali Civili 1, 25123 Brescia, Italy
b Pediatric Surgery Department, Spedali Civili di Brescia, P.le Spedali Civili 1, 25123 Brescia, Italy
c Multiple Sclerosis Center, Spedali Civili di Brescia, Presidio di Montichiari, Via Ciotti 154, 25012 Montichiari, ItalyReceived 18 June 2012; accepted with revision 13 July 2012
Available online 21 July 2012CNS, central nervous system; BM, bo
recombination excision circles; BECs, b
mononuclear cells; TCRAC, TCR consta
memory; PML, progressive multifocal l
⁎ Corresponding author. Fax: +39 030
E-mail addresses: zanotti.cinzia@g
asottini@libero.it (A. Sottini), emirena
sarah.rasia@gmail.com (S. Rasia), rugg
1521-6616/$ - see front matter © 2012
doi:10.1016/j.clim.2012.07.007KEYWORDS
Endothelial transmigration;
Multiple sclerosis;
Natalizumab;
TRECs;
KRECs
Abstract The anti-α4 monoclonal antibody natalizumab inhibits lymphocyte extravasation into
the central nervous system and increases peripheral T and B lymphocytes in multiple sclerosis
patients. To investigate whether the lymphocyte accumulation was due to a higher lymphocyte
production, an altered homeostasis, or a differential transmigration of lymphocyte subsets through
endothelia, T-cell receptor excision circles and kappa-deleting recombination excision circles were
quantified before and after treatment, T-cell receptor repertoire was analyzed by spectratyping,
and T- and B-lymphocyte subset migration was studied using transwell coated with vascular and
lymphatic endothelial cells. We found that the number of newly produced T and B lymphocytes is
increased because of a high release and of a low propensity of naïve subsets to migrate across
endothelial cells. In some patients this resulted in an enlargement of T-cell heterogeneity. Because
new lymphocyte production ensures the integrity of immune surveillance, its quantification could
be used to monitor natalizumab therapy safety.
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Natalizumab is the first monoclonal antibody approved for
the treatment of relapsing–remitting multiple sclerosis (MS)
[1,2]. Its mechanism of action is thought to be mediated
through the block of the binding between the α4 subunit of
the α4β1 (very late antigen-4; VLA-4) and α4β7 integrins on
the lymphocytes of systemic circulation with their ligand,
the vascular cell adhesion molecule 1 (VCAM-1), on vascular
endothelium. Natalizumab also induces a continuous de-
crease of α4 expression [3] that results in a reduced
transmigration of inflammatory cells across the blood–
brain barrier (BBB) into the central nervous system (CNS)
and in an enhancement of the number of B cells, in
particular immature B lymphocytes, CD8+, CD4+ and NK
cells in peripheral blood [4–7]. In treated patients, the
increase of CD34+ precursor cells [8], together with the
transient increase of nucleated immature red cells [9] and
immature B lymphocytes [4] has suggested that natalizumab
can preferentially mobilize immature cell subsets, probably
because of its interference with the binding between VLA-4
and the VCAM-1 on the bone marrow (BM) stromal cells [8]. It
is likely, therefore, that the drug can also affect T- and
B-cell output from their production sites. Furthermore, the
different expression of VLA-4 on lymphocyte subpopulations,
with its basal levels higher on B than on T cells, on CD8+ than
on CD4+ T cells, and on memory than on naïve cells [10,11]
could also imply that natalizumab treatment can differen-
tially influence the homeostasis of lymphocyte subsets. To
verify these possibilities, we monitored the changes in the
number of T and B lymphocytes recently released from
thymus and BM in patients treated with natalizumab by
quantifying the number of T-cell receptor (TCR) excision
circles (TRECs) and kappa-deleting recombination excision
circles (KRECs) [12,13]. KRECs and TRECs are DNA excision
products generated during B- and T-cell receptor gene
rearrangements. Because they do not replicate when cells
proliferate in the periphery, and are lost when the cells die,
their quantification is considered a reliable estimate of the
amount of newly produced B and T lymphocytes [12,13]. The
composition of peripheral lymphocyte pool was studied by
phenotyping T- and B-cell subsets, and by analyzing the
heterogeneity of the TCR repertoire [12] and the replication
history of B lymphocytes [14]. Furthermore, because
natalizumab alters the leukocyte migration, and peripheral
homeostasis could be influenced by the extent of immune
cell trafficking across endothelial barriers, we investigated
whether there is a differential transmigration of lymphocyte
subsets of natalizumab-treated patients through monolayers
of primary cultures of endothelial cells originated from
blood (BECs) or lymphatic (LECs) vessels.
2. Material and methods
2.1. Subjects
The characteristics of the 19 patients with relapsing–
remitting MS included in the study are listed in Supplemen-
tary Table 1. Peripheral blood was obtained before the first
infusion of natalizumab (T0) and then at 6 (T6) and 12
(T12) months of therapy. Controls included age- andgender-matched healthy donors (HDs). The study was
reviewed by the Ethical Committee of the Spedali Civili of
Brescia and informed consent was obtained from all
participants. Peripheral blood was drawn into PAXgene
tubes (PreAnalytiX, Hombrechtikon, Germany) for RNA
preparation and into heparinized tubes for peripheral blood
mononuclear cells (PBMCs) isolation by Ficoll–Hypaque
density gradient centrifugation.
2.2. Quantification of TRECs, KRECs, average number
of B-cell divisions, and TCR repertoire analysis
KRECs and TRECs were simultaneously quantified, together
with the reference gene, a segment of TCR constant alpha
chain (TCRAC), by a duplex quantitative Real-Time PCR
performed on the 7500 Fast Real-Time PCR. The sequences
and the quantity of primers and probes used for the assay, as
well as the amplification schedule, were described else-
where [12,13]. KREC, TREC, and TCRAC copy numbers have
been calculated by extrapolating the respective sample
quantities from the standard curve obtained by tenfold
dilutions (from 106 to 10) of a linearized plasmid DNA,
containing three inserts corresponding to fragments of
KRECs, TRECs and TCRAC. The average number of B-cell
divisions was evaluated as previously reported [12]. The
method used for TCR repertoire analysis was reported in the
Supplementary Material and methods.
2.3. Cytofluorimetric characterization of T- and
B-lymphocyte subpopulations
One million PBMCs of MS patients and HDs were phenotyped
to obtain the percentage of ex vivo cell populations.
Phycoerythrin anti-CD3, allophycocyanin-H7 anti-CD4, phyco-
erythrin-Cy7 anti-CD8, fluorescein isothiocyanate anti-CD45RA
(BD Pharmingen, Heidelberg, Germany), peridin-chlorophyll
protein-Cy5.5 anti-CCR7 (BioLegend, San Diego, CA), and
allophycocyanin anti-CD31 (Miltenyi Biotec GmbH, Bergisch
Gladbach, Germany) monoclonal antibodies (mAbs) were
used for T-cell subpopulation characterization. For B-cell
analysis, PBMCs were stained with different amounts of
peridin-chlorophyll protein-Cy5.5 anti-CD19, allophycocyanin
anti-CD21, fluorescein isothiocyanate anti-IgD, and phycoery-
thrin anti-CD27 (BD Pharmingen) mAbs. Data acquisition
was performed using a six-color two-laser BD FACSCanto II
cytometer and analyzed with the FACS Diva software. The
gating strategy is shown in Supplementary Fig. 1. The same
combinations of mAbs were used to stain cells transmigrated
through the BEC and LEC monolayers, as specified in the
Supplementary Material and methods.
2.4. Culture of BECs and LECs and transmigration
assay
BECs and LECs were isolated from human foreskins of 22
children and adults undergoing surgical procedures. The
methods used for BEC and LEC growth and characterization
as well as the transmigration assay procedure were reported
in the Supplementary Material and methods. Before the
transmigration assay, purified BECs and LECs from different
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differences.
2.5. Statistical analysis
TREC and KREC changes through therapy were analyzed after
log-transformation as specified in the figure legend. The
percentages of T- and B-cell subpopulations, obtained
before and after therapy, and transmigrated through the
BEC or LEC monolayer, were compared by a two-factor
ANOVA model with repeated measures on both factors, and
planned contrasts were performed to test the main effects
and interactions, as detailed in the Supplementary Material
and methods. The significance threshold was set at p=0.05.
3. Results
3.1. New T- and B-cell production and lymphocyte
subset quantification
The number of TRECs and KRECs of natalizumab-treated
patients followed for 12 months of therapy was compared to
that found in HDs (Fig. 1a). The mean level of TRECs in
samples obtained before therapy was only slightly reducedFigure 1 Number of newly produced T and B lymphocytes. a. TREC
were calculated by Real-Time PCR before therapy initiation (T0) and
that of HDs (white dots). b. Number of “recent thymic emigrants”,
cytometric analysis in ex vivo samples at the indicated time points.
comparisons, run after a significant one-factor ANOVA for repeated
HDs, set as the reference group) following a significant one-way ANO
as follows: *: pb0.05, **: pb0.01, and ***: pb0.001.compared to HDs, but increased significantly after therapy
initiation. The lowest levels observed at each time point
belonged to the same patient. Similarly, KRECs increased
during the follow-up, becoming significantly higher than in
HDs after 6 and 12 months of therapy. The natalizumab-
induced expansion of newly produced T and B cells was
confirmed by flow cytometry because both CD4+CCR7+
CD45RA+CD31+ “recent thymic emigrants” and CD8+CCR7+
CD45RA+ naïve lymphocytes, which are the T-cell subtypes
more likely containing the highest number of TRECs [15], as
well as CD19+CD21− immature and CD19+CD21+IgD+CD27−
naïve B cells, which contain the highest number of KRECs
[14], were significantly increased after 6 and 12 months of
therapy (Fig. 1b).
The number of all memory T- and B-lymphocyte subsets
was increased in treated patients in comparison to untreated
patients and, in several cases, to HDs (Supplementary Fig.
2). After calculating the fold-change of the various cell
populations in treated patients, we found that the median of
the T0-to-T12 changes ranged from 1.2- to 1.7-fold within
the various CD4+ cell subsets, while they ranged from 1.8-
and 3.1-fold within the CD8+ populations, and from 1.8- to
4.0-fold within the B-cell subsets. In particular, the
T0-to-T12 fold-increase in both the switched (median: 3.1)
and unswitched (median: 4.0) memory B-cell subsets wasand KREC numbers in natalizumab-treated patients (black dots)
after 6 (T6) and 12 (T12) months of therapy, and compared to
naïve CD8+ cells, immature and naïve B cells obtained by flow
P values were obtained either by Bonferroni-corrected multiple
measures, or by the Dunnett's test (to compare T0, T6, T12 with
VA. The mean values are indicated. Only significant p are shown
22 C. Zanotti et al.significantly higher than in the naïve B cells (median: 1.8;
pb0.01, Dunn's multiple comparison test run after the
Friedman test).3.2. TCR repertoire and B-cell proliferation
The TCR repertoire analysis, performed in samples obtained
before therapy initiation and after 12 months from 10
randomly chosen patients, showed that TCR heterogeneity
was slightly modified by the therapy with the number of TCR
variable beta (TCRBV) chain perturbations decreasing in four
patients (n. 2, 3, 5, and 12) and increasing in four (n. 13, 15,
16 and 17); in the remaining two patients (n. 14, 18), the
same number of perturbed TCRBV chains were observed
before and after the therapy (Fig. 2). In half of the patients
clonal expansions were present in less than 6 TCRBV chains
over the 23 segments analyzed at T0 and/or T12 while, in
the other half, between 6 and 12 TCRBV chains were
perturbed. It is also evident that clonal expansions prefer-
entially involved specific TCRBV chains: the heterogeneity of
TCRBV4+ cells was limited in all patients, both before and
after therapy, whereas that of cells expressing TCRBV18,
TCRBV20 and TCRBV21 segments was limited in most of the
patients. The preferentially expanded TCRBV segments were
TCRBV20 and TCRBV17. These expansions were not associ-
ated with clinical or laboratory signs of infection or with MS
relapses.
The replicative history of the B-cell subpopulations of MS
patients, calculated as the average number of B-cellFigure 2 Analysis of TCR repertoire. The percent usage of TCRBV
CDR3-length distributions were determined by spectratyping analys
12 months (T12). The modifications of TCRBV perturbations wer
mean+2SD (gray squares) of the CDR3 distribution found in HDs. n:
chains were considered overused when their percent usage was highe
n*: number of preferentially expressed TCRBV chains.divisions, was not significantly different between genders
(median at T12: 4.04 in males and 4.39 in females, Mann–
Whitney test, p=NS), did not change significantly with age,
nor was affected by natalizumab therapy, and was similar to
that observed in HDs (Fig. 3a). As found in controls, the
average number of divisions in the total B-cell population of
MS patients correlated inversely with the number of
logKRECs/ml in samples obtained before treatment and
12 months after therapy initiation (Fig. 3b).
3.3. Transmigration of lymphocyte subsets through
BEC and LEC monolayers
Six and 12 months of therapy with natalizumab had only a
little effect on lymphocyte subset transendothelial migra-
tion because the percentage of recovery of the total
population of CD8+ and CD19+ lymphocytes (solid lines of
Fig. 4a), and of naïve and memory unswitched and switched
CD19+ counterparts (solid lines of Fig. 4b) at the bottom of
the BEC- or LEC-coated transwells reflected the effect of the
drug seen in the ex vivo samples. Only the in vitro migration
of CD45RA+ T effector memory (TEMRA) cells through LECs
(bold solid line of Fig. 4b), but not through BECs, appeared
to be selectively modified by 12 months of therapy. A very
slight influence of the therapy was also observed on CD4+
cells because a reduced percentage of CD4+ lymphocytes
was observed after 6 months of therapy in the transmigrated
samples (solid lines of Fig. 4a), while in ex vivo samples the
decrease became apparent only after 12 months of treat-
ment (bold solid line of Fig. 4a). However the drug, that did(from BV1 to BV25) segments and the perturbations of TCRBV
is in samples obtained before therapy initiation (T0) and after
e considered significant when their values were beyond the
number of perturbed TCRBV chains at each time point. TCRBV
r than mean+2SD (“x”) of the TCRBV chain usage found in 5 HDs.
Figure 3 Analysis of B-cell divisions. The average number of B-cell divisions in MS patients and HDs was calculated at the indicated
time points. The statistical analysis was performed using the Friedman test, the comparison of data obtained at T0, T6, and T12 with
those of HDs was done by the Mann–Whitney test, and the correlation of the average number of B-cell divisions with the log number of
KRECs was obtained by the Spearman's test.
Figure 4 Cell subset transmigration across BECs and LECs. PBMCs, obtained before therapy initiation (T0) and after 6 (T6) and 12 (T12)
months, were either subjected to flow cytometric analysis to obtain the percentage of cell subsets in the ex vivo condition, or added to
the top of the BEC and LEC monolayers and allowed to transmigrate to the bottom chamber. All transmigrated cells were then collected,
counted, stained with labelled monoclonal antibodies and phenotyped. a. Percentages of ex vivo and transmigrated CD4+ and CD8+ T
lymphocytes and CD19+ B cells. b. Percentages of ex vivo and transmigrated CD4+ and CD8+ T-cell subsets and CD19+ B-cell
subpopulations. The percentages of ex vivo and transmigrated “recent thymic emigrants” are depicted as hatched bars. Statistical
analysis was performed by two-factor ANOVA with repeated measures on both factors, as detailed in the Supplementary Material and
methods. Bars indicate the mean percentage of the cell subsets analyzed in the three experimental conditions; error bars indicate ±SD;
dashed lines indicate significant differences between the mean cell percentages in the three experimental conditions (ex vivo vs. BEC
vs. LEC transmigration); solid lines indicate the significant differences due to the therapy observed at T6 in comparison to T0; bold solid
lines indicate peculiar therapy-induced changes in cell percentages (e.g. present in the ex vivo just at T12, or only after passage through
one of two types of endothelium). TCM: T central memory cells; TEM: T effector memory cells. *: pb0.05, **: pb0.01, and ***: pb0.001.
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vivo samples, also seemed to be completely ineffective in
altering the percentage of CD4+ cell subsets which migrated
through BEC- or LEC-coated transwells (Fig. 4b). Neverthe-
less, the most relevant result of the transmigration assay is
that, independently of the therapy, the mean percentages
of CD4+, CD8+ and CD19+ lymphocytes recovered at the
bottom of coated transwell inserts were, respectively,
significantly higher, lower and unmodified with respect to
those observed in the ex vivo samples (dotted lines of
Fig. 4a); the same features, however, were also observed
using lymphocyte subsets prepared from HDs (Supplementa-
ry Fig. 3a). Furthermore, naïve CD4+ and CD8+ lymphocytes
showed a worse propensity to migrate across BECs and LECs
than their memory counterparts in both patients and HDs
(Fig. 4b and Supplementary Fig. 3b). A similar situation was
observed for the naïve B-cell subset, whereas a significant
mean percent increase of immature B cells and a decrease of
memory unswitched B cells were found after transmigration
only in MS patients and not in HDs. Finally, independently of
the treatment, a selective effect due to the type of
endothelial cells coated on the transwell inserts, appeared
to affect only the migration of CD4+ central memory
population, which passed more preferentially through the
BEC than through the LEC monolayer; on the contrary,
memory unswitched B-lymphocyte percentage was slightly
increased when these cells transmigrated through the LEC
monolayer.4. Discussion
Natalizumab treatment has been shown to reduce the
migration of leukocytes into the CNS [1,6,11,16,17], to inhibit
the retention of memory- andmarginal zone-like B cells within
the spleen [6] and to induce a sequestration of lymphocytes, in
particular activated T cells [18], and of immature B cells [4] in
the peripheral circulation of MS-treated patients. However,
considering the scarcity of leukocytes in the CNS compared to
the periphery and the slight contribution of memory- and
marginal zone-like B cells on the composition of the lymphocyte
pool, it is unlikely that the reducedmigration of leukocytes into
the CNS and the decreased retention of specific B-cell subsets in
the spleen can quantitatively affect peripheral lymphocyte
count or fully explain the increase of lymphocytes observed
during natalizumab therapy. Instead, by using the TREC and
KREC assay we found that newly produced T and B lymphocytes
were significantly increased in peripheral blood of patients
treated for 6 and 12 months with natalizumab, thus indicating
that the drug may influence the lymphocyte release from
production sites. The increased production of new T and B
lymphocytes was confirmed by flow cytometry that also
demonstrated an augmented number of RTE and naïve CD4+
cells in treated patients while, as also shown by Planas et al. [6],
the percentage of these cell subsets remained unmodified.
Considering that T cells of natalizumab-treated patients
undergo activation and differentiation in the secondary
lymphoid organs and then remained sequestered in the
circulation [18] and that every perturbation in the number
and longevity of naïve and memory lymphocyte populations
must be balanced by counteracting mechanisms that try to
keep the balance between the different compartments[19,20], it is likely that the high number of TRECs results
from the increased thymic release necessary to maintain the
T-cell pool homeostasis. This possibility is supported by the
finding that reduction of VLA-4 levels also renders mature
thymocytes less adhesive to the thymic stromal cells, thus
more easily released into circulation [21]. Our data also
show that the number of TRECs found in pre-therapy samples
was similar to that of age- and gender-matched HDs, while
previous results reported that thymic output is low in
untreated MS patients [22,23]. One possible explanation
can be that all but one of our patients had been previously
treated with immunomodulatory drugs, whereas, in the
other studies they were naïve for therapy. In addition, flow
cytometry confirmed that the pre-therapy number of
“recent thymic emigrants” was comparable to that of
controls and showed that newly released naïve CD4+ and
CD8+ lymphocytes were both increased in treated patients.
In some treated patients, despite the very short duration
of the therapy, the thymic output of new T-cell specificities
resulted in a mild enlargement of the T-cell heterogeneity.
Actually, wide T-cell repertoire changes are unexpected
since a renewal of TCR diversity may require a long time
and, for instance, modifications of T-cell repertoire have
been observed in MS patients only after two years since BM
transplantation [24]. In some other treated patients the
T-cell diversity appeared to be reduced, as expected,
forasmuch as circulating CD8+ lymphocytes, which are the
cells that preferentially expanded clonally [25], resulted
increased in our treated patients. Flow cytometric analysis
also indicated that the observed increase of KRECs in the
peripheral blood is likely to be sustained by the rise of
immature and naïve B cells. Nevertheless, the majority of B
cells in peripheral blood of treated patients were unswitched
and switched memory B cells, which are known to undergo an
antigen-independent (homeostatic) proliferation [14]. How-
ever, the comparable average number of B-cell divisions we
have found before and after therapy supports the hypothesis
that the natalizumab-induced increase of memory B cells is
due to an inhibited retention in the spleen [6] more than a
peripheral proliferation.
Another reason for the accumulation of cells containing
TRECs and KRECs during time in natalizumab-treated
patients could be a drug-induced inhibition of trafficking
through endothelial cells. This is an important issue since
the regulation of immune cell trafficking across endothelial
barriers is critical for immune cell maturation and for
mounting of appropriate responses within specific organ
compartments. In MS patients, this is even more crucial
because deficits of immune surveillance, including defects
in new T- and B-cell production and in the ability of immune
cells to transmigrate across the BBB, may predispose to
progressive multifocal leukoencephalopathy (PML) [26,27].
In transmigration assays performed to measure the migrato-
ry capacity of lymphocytes, BBB-endothelial cells have been
previously used either untreated, activated, or triggered by
a gradient of chemoattractants [27–29] because, during the
MS-associated inflammatory process, activated meningeal or
BBB-endothelial cells amplify the migration of immune cells
to the CNS parenchyma in a multi-step process that involves
selectins, chemokines (and their receptors) and cell adhe-
sion molecules [28]. Because in MS patients, trafficking
through non-BBB endothelial cells probably takes place in
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gration assay with non‐activated BECs and LECs, thus
avoiding the addition of any exogenous cytokine (exception
made for the VEGF used for cell growth) that would make
results difficult to be interpreted. In this setting, the
transmigration is mediated only by the interaction of
integrins present on lymphocyte surface with their ligands
on endothelial cells [30]. In these experimental conditions,
using all the appropriate controls, we demonstrated that
natalizumab therapy only marginally interferes with the
ability of T and B lymphocytes to pass through non‐activated
monolayers of BECs and LECs. Indeed, natalizumab therapy
showed a minimal inhibitory effect on CD4+ cells transmi-
gration and induced an increased passage of TEMRA+ cells
through LEC monolayers, but the other modifications
observed in the percentages of remaining T- and B-cell
subsets collected after migration merely recalled the
therapy-induced subset changes observed in the ex vivo
samples. Thus, lymphocyte trafficking through vascular or
lymphatic endothelium is only barely modified by the
therapy in condition of basal trafficking. On the contrary,
we found that, independently from the treatment, CD4+ and
CD8+ cells with phenotypic characteristics of T central
memory, T effector memory, and TEMRA+ cells have a
higher migratory capacity than their naïve counterparts both
in MS patients and HDs. Therefore, CD8+ effector memory T
lymphocytes transmigrate more readily not only across
BBB-endothelial cells than CD8+ non-effector memory coun-
terpart [28], but they also can more efficiently migrate across
BECs and LECs than the naïve CD8+ subpopulation. However,
again, this feature was observed within CD8+ lymphocytes of
both MS patients and HDs. Collectively, our findings indicate
that the differential migration rates through vascular and
lymphatic endothelium are most likely derived from the
different basal expression of α4 integrin on distinct T and B
subsets and not from natalizumab treatment. Furthermore,
the data ruled out the possibility that non‐activated endothe-
lial cells are a passive barrier, without a role in lymphocyte
migration. Finally, one possible explanation for the lack of
differential lymphocyte transmigration through the two
different types of endothelium (the only exceptions being
CD4+ T central memory cells and memory unswitched B cells)
is the similar level of VCAM-1 found on BEC- and LEC-cell
surface [31]. These transmigration data only apparently
contradict previously published results demonstrating a
reduced transmigration of lymphocytes obtained from
natalizumab-treated patients [27,28] because these studies
were obtained using very different experimental conditions,
including the use of purified lymphocyte subsets and of human
brain microvascular endothelial cells, activated with different
stimuli. Indeed, lymphocyte transmigration is a process that is
strictly regulated in conditions of both homeostasis and
inflammation [32] and therefore the mechanisms involved in
this process can vary substantially as a direct reflection of the
involved lymphocyte subsets, the wide range of endothelia
encountered in the vasculature, and activation conditions of
both. Further studies will be needed to verify whether these
findings can be confirmed when a transmigration model
through brain microvascular endothelial cells is employed.
Considering that the JC virus enters the CNS in a non-mutant
form and capsid protein VP1 mutations can originate and be
positively selected within the CNS [33], and that a decreasedproduction of new T and B cells was found in a patient with
PML [26], it is likely that the lower capability of naïve cells to
cross the BBB may contribute to the local reduction of
lymphocyte specificities recognizing mutated viral proteins,
which should be a crucial prerequisite for controlling JC-virus
induced PML.
5. Conclusions
Because a good thymic and BM output assures the continuous
renewal of the immune compartments and the subsequent
integrity of the immune response, the measure of TRECs and
KRECs could be a very useful tool to estimate the activity of
natalizumab and, possibly, to identify those patients that,
having an altered thymic and BM output, could be at risk of
developing PML.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.clim.2012.07.007.
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